Business
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. has received an Institutional Review Board (IRB) waiver to initiate a market research study to gather and evaluate consumer feedback regarding the use of the Company’s 3CL protease inhibitor immune support dietary supplement products Tollovid® and Tollovid Daily™ in their COVID and Long COVID (aka Post-Acute Sequalae of SARS-CoV-2, or “PASC”) journeys. The objective of the study will be to determine whether there is sufficient real-world evidence to support a potential product development program for Tollovid and/or Tollovid Daily in the treatment of Acute COVID and/or Long COVID. Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID. In the weeks ahead, the Company will be contacting customers electronically to complete surveys prepared by our team of physician-scientists to help guide our next steps. Concurrent with this announcement, the Company announced that it will be offering a 50% discount on the price of Tollovid Maximum Strength through close of business on May 31st, 2022. Amazon – Tollovid® Maximum Strengthwww.MyTollovid.com “In the last year we have heard anecdotal reports from customers who have experienced great success using our dietary supplements,” said Gerald E. Commissiong, President and CEO of Todos Medical. “These reports eventually piqued the curiosity of physicians who successfully used our products to help patients, with two such successful Long COVID case studies having been made public and several others in various stages of completion. Based on these, we are preparing for an observational study for Tollovid in Long COVID, and have received overwhelming interest from physicians and patients in participating. This surprising level of interest was the impetus behind accelerating our data gathering efforts by starting the assessment of Tollovid and Tollovid Daily in our existing customer base to determine whether the reviews and anecdotal reports we have heard from clients are in fact part of...